FDA Grants Rolling Review and CNPV Designation to Compass Pathways (CMPS) for TRD Treatment

23 hours ago 1

Maham Fatima

Mon, April 27, 2026 astatine 1:21 AM CDT 2 min read

Compass Pathways (NASDAQ:CMPS) is 1 of the small headdress stocks with the highest upside potential. On April 24, Compass Pathways announced that the US FDA granted a rolling reappraisal for its NDA and selected COMP360 for the Commissioner’s National Priority Voucher/CNPV program. COMP360 is simply a proprietary synthetic psilocybin formulation designed for patients with treatment-resistant depression/TRD.

The CNPV designation provides the institution with enhanced regulatory connection and a importantly shortened reappraisal timeline of 1 to 2 months erstwhile the exertion is filed, though the cause indispensable inactive conscionable each modular FDA requirements for information and efficacy. The determination is supported by affirmative information from 2 ample Phase 3 objective trials involving implicit 1,000 participants. These trials demonstrated that COMP360 could nutrient clinically meaningful effects arsenic rapidly arsenic 1 time aft administration, with results lasting astatine slightest six months for galore patients.

FDA Grants Rolling Review and CNPV Designation to Compass Pathways (CMPS) for TRD Treatment

25 Best Online Psychology Degree Programs Heading Into 2024

The information illustration indicated that astir adverse events were mild to mean and typically resolved wrong 24 hours. The CEO emphasized that this regulatory advancement validates the urgent request for innovation successful the intelligence wellness field, peculiarly for the estimated 4 cardinal radical successful the US surviving with TRD. As the astir precocious institution successful the tract of classical psychedelics, Compass Pathways (NASDAQ:CMPS) is presently preparing for the commercialized motorboat of COMP360.

Compass Pathways (NASDAQ:CMPS) is simply a biotech institution focused connected processing psychedelic treatments for intelligence wellness issues. Its flagship cause campaigner COMP360 is being developed arsenic a solution for treatment-resistant slump arsenic good arsenic post-traumatic accent disorder.

While we admit the imaginable of CMPS arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey connected Google News.

Read Entire Article